<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080712</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00992</org_study_id>
    <nct_id>NCT05080712</nct_id>
  </id_info>
  <brief_title>Progression of Atrial Fibrillation in the Young</brief_title>
  <acronym>PRAY</acronym>
  <official_title>Progression of Atrial Fibrillation in the Young</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boeringer Ingelheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the presence and magnitude of structural changes&#xD;
      of the heart and their long-term development in young patients with atrial Fibrillation (AF),&#xD;
      studied by echocardiographic measurements and plasma biomarkers and their association to AF&#xD;
      burden, studied using long-term ECG&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with symptomatic Atrial Fibrillation diagnosis are included. Diagnosis is set&#xD;
      either at the index visit or within 12 months before inclusion. . The follow up period is 5&#xD;
      years. Patients presenting with AF in connection with acute infection, acute cardiac&#xD;
      ischemia, surgery or thyroid disease are excluded. Further, AF patients with&#xD;
      cardiomyopathies, known genetic diseases and congenital cardiac abnormalities are also&#xD;
      excluded.&#xD;
&#xD;
      At inclusion patients undergo an in-depth interview regarding comorbidities, medication,&#xD;
      previous treatments related to the AF diagnosis. In addition, baseline data for weight and&#xD;
      height are collected.&#xD;
&#xD;
      In connection to inclusion the patients are asked leave venous bloodwork (Na, K, Creatinine,&#xD;
      plasma Glucose and NTproB-Type Natriuretic Peptide). An echocardiographic exam is performed&#xD;
      according to a prespecified protocol with special emphasis on the left atrial function and&#xD;
      anatomy. This is followed by a continuous ECG recording for 14 days using BioTel ePatch. The&#xD;
      ECG patch is later returned to a core facility by mail.&#xD;
&#xD;
      The patients´ are followed for five years and are asked to leave bloodwork and perform a&#xD;
      14-day ECG recording yearly. After these exams, a follow up phone call is placed to the&#xD;
      patient aimed at documenting clinical progress related to symptoms, treatment and&#xD;
      interventions. After 5 years follow up patients undergo a follow up echocardiographic exam in&#xD;
      addition to yearly bloodwork and ECG recording. The patients´ clinical symptoms are treated&#xD;
      at the clinician´s discretion according to current guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of atrial fibrillation burden</measure>
    <time_frame>change from baseline at 5 years</time_frame>
    <description>Change in burden of atrial fibrillation expressed as proportion of arrhythmia present on long-term ECG yearly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of humoral measures of hemodynamic status</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in levels of plasma-N-terminal pro brain natriuretic peptide yearly (ng)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of atrial electrocardiographic status</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in number of supraventricular ectopic beats per 24 h on long-term ECG Yearly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of supraventricular ectopies</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in numbers of supraventricular tachycardia runs of at least 20 beats per 24 h on long-term ECG yearly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of atrial fibrillation incident</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in numbers of atrial fibrillation episodes per 24 h on long-term ECG yearly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of echocardiographic status</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in the left atrial volume indexed (ml/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of left atrial systolic function by echocardiography</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in left atrial strain (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of left atrial volume by echocardiography</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in left ventricular volume indexed (ml/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of left ventricular systolic function by echocardiographic</measure>
    <time_frame>Change from baseline at 5 years</time_frame>
    <description>Change in left ventricular ejection fraction (%)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with new onset atrial fibrillation within 12 months from inclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Diagnosis of atrial fibrillation within one year of inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Duration of atrial fibrillation over one year.&#xD;
&#xD;
          -  Acute stressor for atrial fibrillation such as: acute ischemic heart disease or&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Sobocinski Doliwa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet Danderyds University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Sobocinski Doliwa, M.D. Ph.D.</last_name>
    <phone>+46812357556</phone>
    <email>piotr.sobocinski-doliwa@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Engdahl, MD PhD</last_name>
    <email>johan.engdahl@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Sobocinski Doliwa, M.D. Ph.D.</last_name>
      <email>piotr.sobocinski-doliwa@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Johan Engdahl</last_name>
      <email>johan.engdahl@sll.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Piotr Sobocinski Doliwa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>progression</keyword>
  <keyword>left atrial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

